|
Address: |
Office 901 - AL Thuraya Tower 1, Dubai Media City |
| |
Dubai, United Arab Emirates |
| Tel: |
+971 4 3692931 |
| Fax: |
+971 4 3688299 |
| Email: |
|
| Website: |
www.amgen.com |
Amgen, a pioneer in biotechnology, harnesses the power of cellular and molecular biology and medicinal chemistry to discover develop and deliver innovative human therapeutics. For more than thirty years, Amgen science has generated important medical discoveries, resulting in medicines that have helped millions of patients fight cancer, kidney disease, rheumatoid arthritis, and other serious illnesses.
With a deep and broad pipeline of potential new therapeutic candidates, and active research programs in oncology, inflammation, metabolic and bone disorders, hematology, nephrology, and neuroscience, we are dedicated to advancing science to help patients. That dedication shows in our interdisciplinary and modality-independent approach to research and development. Amgen scientists first identify a disease target and then select the best modality – protein, small molecule, or antibody – to interact with that target to block the disease process.
Amgen has one of the richest pipelines in the biotech industry (and won the prestigious Scrip Best Pipeline and Best Drug for Nplate awards in 2009 and Best Drug for Prolia in 2010) and one of the most potentially promising in the whole human therapeutics area.
To fully realize the promise of biotechnology and to dramatically improve people’s lives, we extend science beyond the lab and clinic, into the production plant. Amgen is recognized worldwide for unparalleled expertise in the complex field of biologics manufacturing. We currently produce more than a third of the world’s non-vaccine and non-insulin protein therapeutics.
Headquartered in Southern California, with offices or subsidiaries in more than 30 countries, Amgen is traded on the NASDAQ stock exchange under the symbol AMGN.
|
